ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BNT Basepoint

14.75
0.00 (0.00%)
18 Oct 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Basepoint LSE:BNT London Ordinary Share GB0007381295 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.75 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Bentley Pharmaceuticals to Present at the UBS Global Specialty Pharmaceuticals Conference

24/05/2004 3:46pm

PR Newswire (US)


Basepoint (LSE:BNT)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more Basepoint Charts.
Bentley Pharmaceuticals to Present at the UBS Global Specialty Pharmaceuticals Conference EXETER, N.H., May 24 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on advanced drug-delivery technologies, which also manufactures and markets generic and branded products in Europe, announced today that Michael D. Price, Vice President and Chief Financial Officer of the Company, will be presenting at the UBS Global Specialty Pharmaceuticals Conference at the Grand Hyatt in New York, NY. The presentation is scheduled for Tuesday, May 25, 2004 at 3:00 p.m. (EDT). The presentation will be broadcast live over the Internet and may be accessed via the Company's website, http://www.bentleypharm.com/. In addition, a replay of the presentation will be available beginning three hours after the presentation time and will remain available through June 27, 2004. Follow the above instructions to access the replay. Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and sells active pharmaceutical ingredients through its subsidiary, Bentley API. Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at http://www.bentleypharm.com/. DATASOURCE: Bentley Pharmaceuticals, Inc. CONTACT: Michael D. Price, Vice President, Chief Financial Officer of Bentley Pharmaceuticals, Inc., +1-603-658-6100; Investors - Jonathan Birt, Lanie Marcus or Media - Sean Leous, all of Financial Dynamics, +1-212-850-5600, for Bentley Pharmaceuticals, Inc. Web site: http://www.bentleypharm.com/

Copyright

1 Year Basepoint Chart

1 Year Basepoint Chart

1 Month Basepoint Chart

1 Month Basepoint Chart

Your Recent History

Delayed Upgrade Clock